In 2019, US FDA approved atezolizumab in combination with nab‐paclitaxel for the first‐line treatment of unresectable locally advanced or metastatic PD‐L1 positive TNBC, making it the first immunotherapy regimen for breast cancer. This evidence concerns the gene CD274 and breast carcinoma.